Inhibition of serum-stimulated mitogen activated protein kinase by 1α,25(OH)2-vitamin D3 in MCF-7 breast cancer cells
1α,25-Dihydroxyvitamin D3 [1α,25(OH) 2D3], the hormonally active form of vitamin D3, has been shown to be a potent negative growth regulator of breast cancer cells both in vitro and in vivo. 1α,25(OH)2D3 acts through two different mechanisms. In addition to regulating gene transcription via its spec...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2004
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 16765caa a22017897a 4500 | ||
|---|---|---|---|
| 001 | PAPER-21130 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205233.0 | ||
| 008 | 190411s2004 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-16544373001 | |
| 024 | 7 | |2 cas |a calcitriol, 32222-06-3, 32511-63-0, 66772-14-3; mitogen activated protein kinase 1, 137632-08-7; mitogen activated protein kinase 3, 137632-07-6; mitogen activated protein kinase, 142243-02-5; orthovanadic acid, 14333-18-7; protein tyrosine kinase, 80449-02-1; phosphotyrosine, 21820-51-9; protein tyrosine phosphatase, 79747-53-8, 97162-86-2; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; Calcitriol, 32222-06-3; Enzyme Inhibitors; Mitogen-Activated Protein Kinases, EC 2.7.1.37; Phosphotyrosine, 21820-51-9; Protein-Tyrosine-Phosphatase, EC 3.1.3.48; Proto-Oncogene Proteins pp60(c-src), EC 2.7.1.112; Pyrazoles; Pyrimidines; Receptors, Calcitriol | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a JCEBD | ||
| 100 | 1 | |a Capiati, D.A. | |
| 245 | 1 | 0 | |a Inhibition of serum-stimulated mitogen activated protein kinase by 1α,25(OH)2-vitamin D3 in MCF-7 breast cancer cells |
| 260 | |c 2004 | ||
| 270 | 1 | 0 | |m Boland, R.L.; Dept. Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, 8000 Bahía Blanca, Argentina; email: rboland@criba.edu.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Anderson, D., Koch, C.A., Grey, L., Ellis, C., Moran, M.F., Pawson, T., Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors (1990) Science, 250, pp. 979-982 | ||
| 504 | |a Assoian, R.K., Control of the G1 phase cyclin-dependent kinases by mitogenic growth factors and the extracellular matrix (1997) Cytokine Growth Factor Rev, 8, pp. 165-170 | ||
| 504 | |a Banerjee, P., Chatterjee, M., Antiproliferative role of vitamin D and its analogs-A brief overview (2003) Mol Cell Biochem, 253, pp. 247-254 | ||
| 504 | |a Baran, D.T., Quail, J.M., Ray, R., Leszyk, J., Honeyman, T., Annexin II is the membrane receptor that mediates the rapid actions of 1alpha,25-dihydroxyvitamin D3 (2000) J Cell Biochem, 78, pp. 34-46 | ||
| 504 | |a Bratland, A., Risberg, K., Maelandsmo, G.M., Gutzkow, K.B., Olsen, O.E., Moghaddam, A., Wang, M.Y., Ree, A.H., Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D2 in breast cancer cells (2000) Cancer Res, 60, pp. 5578-5583 | ||
| 504 | |a Brown, M.T., Cooper, J.A., Regulation, substrates and functions of src (1996) Biochim Biophys Acta, 1287, pp. 121-149 | ||
| 504 | |a Buitrago, C., Vazquez, G., De Boland, A.R., Boland, R., Activation of Src kinase in skeletal muscle cells by 1,25(OH) 2-vitamin D3 correlates with tyrosine phosphorylation of the vitamin D receptor (VDR) and VDR-Src interaction (2000) J Cell Biochem, 79, pp. 274-281 | ||
| 504 | |a Cano, E., Mahadevan, L.C., Parallel signal processing among mammalian MAPKs (1995) Trends Biochem Sci, 20, pp. 117-122 | ||
| 504 | |a Capiati, D.A., Benassati, S., Boland, R., 1,25(OH)2-vitamin D3 induces translocation of the vitamin D receptor (VDR) to the plasma membrane in skeletal muscle cells (2002) J Cell Biochem, 86, pp. 128-135 | ||
| 504 | |a Chen, P.S., Toribara, T.Y., Warner, H., Microdetermination of phosphorus (1956) Anal Biochem, 28, pp. 1756-1761 | ||
| 504 | |a Colston, K.W., Hansen, C.M., Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer (2002) Endocr Relat Cancer, 9, pp. 45-59 | ||
| 504 | |a Davis, R.J., MAPKs: New JNK expands the group (1994) Trends Biochem Sci, 19, pp. 470-473 | ||
| 504 | |a De Boland, A., Nemere, I., Rapid actions of vitamin D compounds (1992) J Cell Biochem, 49, pp. 32-36 | ||
| 504 | |a DeLuca, H.F., The vitamin D story: A collaborative effort of basic science and clinical medicine (1988) FASEB J, 2, pp. 224-236 | ||
| 504 | |a Fisher, E.H., Charbonneau, H., Tonks, N.F., Protein tyrosine phosphatases: A diverse family of intracellular and transmembrane enzymes (1991) Science, 253, pp. 401-406 | ||
| 504 | |a Frame, M.C., Src in cancer: Deregulation and consequences for cell behaviour (2002) Biochim Biophys Acta, 1602, pp. 114-130 | ||
| 504 | |a Gomperts, B.D., Kramer, I.M., Tatham, P.E.R., Growth factors: Setting the framework (2002) Signal Transduction, pp. 225-255. , Gomperts BD, Kramer IM, Tatham PR, editors. San Diego: Academic Press | ||
| 504 | |a Hall, R.A., Premont, R.T., Lefkowitz, R.A., Heptahelical receptor signaling: Beyond the G protein paradigm (1999) J Cell Biol, 145, pp. 927-932 | ||
| 504 | |a Kim, Y.S., MacDonald, P.N., Dedhar, S., Hruska, K.A., Association of 1 alpha,25-dihydroxyvitamin D3-occupied vitamin D receptors with cellular membrane acceptance sites (1996) Endocrinology, 137, pp. 3649-3658 | ||
| 504 | |a Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage (1970) Nature, 227, pp. 680-685 | ||
| 504 | |a Liu, M., Lee, M.H., Cohen, M., Bommakanti, M., Freedman, L.P., Transcriptional activation of the Cdk inhibitor p21 by vitamin D 3 leads to the induced differentiation of the myelomonocytic cell line U937 (1996) Genes Dev, 10, pp. 142-153 | ||
| 504 | |a Luttrell, L.M., Roudabush, F.L., Choy, E.W., Miller, W.E., Field, M.E., Pierce, K.L., Lefkowitz, R.J., Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds (2001) Proc Natl Acad Sci USA, 98, pp. 2449-2454 | ||
| 504 | |a Mehta, R.G., Mehta, R.R., Vitamin D and cancer (2002) J Nutr Biochem, 13, pp. 252-264 | ||
| 504 | |a Minghetti, P., Norman, A., 1,25(OH)2-vitamin D3 receptors: Gene regulation and genetic circuitry (1988) FASEB J, 2, pp. 3043-3053 | ||
| 504 | |a Monje, P., Zanello, S., Holick, M., Boland, R., Differential cellular localization of estrogen receptor α in uterine and mammary cells (2001) Mol Cell Endocrinol, 181, pp. 117-129 | ||
| 504 | |a Nada, S., Okada, M., MacAuley, A., Cooper, J.A., Nakagawa, H., Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src (1991) Nature, 351, pp. 69-72 | ||
| 504 | |a Nemere, I., Farach-Carson, M.C., Membrane receptors for steroid hormones: A case for specific cell surface binding sites for vitamin D metabolites and estrogens (1998) Biochim Biophys Res Commun, 248, pp. 443-449 | ||
| 504 | |a Nemere, I., Dormanen, M.C., Hammond, M.W., Okamura, W.H., Norman, A.W., Identification of a specific binding protein for 1 alpha,25- dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia (1994) J Biol Chem, 269, pp. 23750-23756 | ||
| 504 | |a Norman, A.W., Olivera, C.J., Barreto Silva, F.R., Bishop, J.E., A specific binding protein/receptor for 1α,25-dihydroxyvitamin D3 is present in an intestinal caveolae membrane fraction (2002) Biochem Biophys Res Commun, 298, pp. 414-419 | ||
| 504 | |a Perlman, K.A., Kutnerei, A., Prahl, J., Smith, C., Inaba, M., Schnoes, H., DeLuca, H.F., 24-Homologated 1,25-dihydroxyvitamin D3 compounds: Separation of calcium and cell differentiation activities (1990) Biochemistry, 29, pp. 190-196 | ||
| 504 | |a Piwnica-Worms, H., Saunders, K.B., Roberts, T.M., Smith, A.E., Cheng, S.H., Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src (1987) Cell, 49, pp. 75-82 | ||
| 504 | |a Reichel, H., Koeffler, H., Norman, A.W., The role of the vitamin D endocrine system in health and disease (1989) New Engl J Med, 320, pp. 980-991 | ||
| 504 | |a Rossi, A.M., Picotto, G., De Boland, A.R., Boland, R.L., Evidence on the operation of ATP-induced capacitative calcium entry in breast cancer cells and its blockade by 17beta-estradiol (2002) J Cell Biochem, 87, pp. 324-333 | ||
| 504 | |a Santillán, G.E., Boland, R., Studies suggesting the participation of protein kinase A in 1,25(OH) 2-vitamin D3-dependent protein phosphorylation in cardiac muscle (1998) J Mol Cell Cardiol, 30, pp. 225-233 | ||
| 504 | |a Santillán, G.E., Vazquez, G., Boland, R., Activation of a β-adrenergic-sensitive signal transduction pathway by the secosteroid hormone 1,25(OH)2-vitamin D3 in chick heart (1999) J Mol Cell Cardiol, 31, pp. 1095-1104 | ||
| 504 | |a Schaeffer, H.J., Weber, M.J., Mitogen-activated protein kinases: Specific messages from ubiquitous messengers (1999) Mol Cell Biol, 19, pp. 2435-2444 | ||
| 504 | |a Sicheri, F., Kuriyan, J., Structures of Src-family tyrosine kinases (1997) Curr Op Struct Biol, 9, pp. 777-785 | ||
| 504 | |a Song, X., Bishop, J.E., Okamura, W.H., Norman, A.W., Stimulation of phosphorylation of mitogen-activated protein kinase by 1alpha,25-dihydroxyvitamin D3 in promyelocytic NB4 leukemia cells: A structure-function study (1998) Endocrinology, 139, pp. 457-465 | ||
| 504 | |a Sun, H., Charles, C.H., Lau, L.E., Tonks, N.K., MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo (1993) Cell, 75, pp. 487-493 | ||
| 504 | |a Superti-Furga, G., Courtneidge, S.A., Structure-function relationships in Src family and related protein tyrosine kinases (1995) BioEssays, 17, pp. 321-330 | ||
| 504 | |a Suzuki, Y., Hruska, K.A., Reid, I., Alvarez, U.M., Avioli, L.M., Characterization of phospholipase C activity of the plasma membrane and cytosol of an osteoblast-like cell line (1989) Am J Med Sci, 297, pp. 135-144 | ||
| 504 | |a Van Weelden, K., Flanagan, L., Binderup, L., Tenniswood, M., Welsh, J., Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089 (1998) Endocrinology, 139, pp. 2102-2110 | ||
| 504 | |a Verbeek, B.S., Vroom, T.M., Adriaansen-Slot, S.S., Ottenhoff-Kalff, A.E., Geertzema, J.G., Hennipman, A., Rijksen, G.J., c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis (1996) Pathol, 180, pp. 383-388 | ||
| 504 | |a Verlinden, L., Verstuyf, A., Convents, R., Marcelis, S., Van Camp, M., Bouillon, R., Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells (1998) Mol Cell Endocrinol, 142, pp. 57-65 | ||
| 504 | |a Verlinden, L., Verstuyf, A., Van Camp, M., Marcelis, S., Sabbe, K., Zhao, X.Y., De Clercq, P., Bouillon, R., Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo (2000) Cancer Res, 60, pp. 2673-2679 | ||
| 504 | |a Walters, M., Newly identified actions of the vitamin D endocrine system (1992) Endocr Rev, 13, pp. 719-764 | ||
| 504 | |a Wang, X., Studzinski, G.P., Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells (2001) J Cell Biochem, 80, pp. 471-482 | ||
| 504 | |a Wang, B., Lemay, S., Tsai, S., Veillette, A., SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF (2001) Mol Cell Biol, 21, pp. 1077-1088 | ||
| 504 | |a Welsh, J.E., Wietzke, J.A., Zinser, G.M., Smyczek, S., Romu, S., Tribble, E., Welsh, J.C., Narvaez, C.J., Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer (2002) J Steroid Biochem Mol Biol, 83, pp. 85-92 | ||
| 504 | |a Xu, W., Harrison, S.C., Eck, M.J., Three-dimensional structure of the tyrosine kinase c-Src (1997) Nature, 385, pp. 595-602 | ||
| 520 | 3 | |a 1α,25-Dihydroxyvitamin D3 [1α,25(OH) 2D3], the hormonally active form of vitamin D3, has been shown to be a potent negative growth regulator of breast cancer cells both in vitro and in vivo. 1α,25(OH)2D3 acts through two different mechanisms. In addition to regulating gene transcription via its specific intracellular receptor (vitamin D receptor, VDR), 1α,25(OH) 2D3 induces rapid, non-transcriptional responses involving activation of transmembrane signal transduction pathways, like growth factors and peptide hormones. The mechanisms that mediate the antiproliferative effects of 1α,25(OH)2D3 in breast cancer cells are not fully understood. Particularly, there is no information about the early non-genomic signal transduction effectors modulated by the hormone. The present study shows that 1α,25(OH)2D3 rapidly inhibits serum induced activation of ERK-1 and ERK-2 MAP kinases. The tyrosine kinase Src is involved in the pathway leading to activation of ERK 1/2 by serum. Furthermore, 1α,25(OH)2D3 increases the tyrosine-phosphorylated state of Src and inhibits its kinase activity, while induces the association of the VDR with Src, either in the presence or absence of serum. In parallel, the hormone rapidly increases the amounts of VDR associated to plasma membranes (PM). Pretreatment with the tyrosine phosphatase inhibitors orthovanadate or bpV (phen) prevented mitogen-activated protein kinase (MAPK) inhibition by 1α,25(OH)2D3. These data altogether suggest that 1α,25(OH)2D3 inhibits the MAPK cascade by inactivating Src tyrosine kinase through a mechanism mediated by the VDR and tyrosine phosphatases. © 2004 Wiley-Liss, Inc. |l eng | |
| 593 | |a Instituto de Ingeniería Genética y Biología Molecular, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina | ||
| 593 | |a Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, 8000 Bahía Blanca, Argentina | ||
| 593 | |a Dept. Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, 8000 Bahía Blanca, Argentina | ||
| 690 | 1 | 0 | |a 1Α,25(OH)2D3 |
| 690 | 1 | 0 | |a BREAST CANCER CELLS |
| 690 | 1 | 0 | |a MAP KINASE |
| 690 | 1 | 0 | |a SRC |
| 690 | 1 | 0 | |a TYROSINE PHOSPHATASES |
| 690 | 1 | 0 | |a VDR |
| 690 | 1 | 0 | |a CALCITRIOL |
| 690 | 1 | 0 | |a GROWTH FACTOR |
| 690 | 1 | 0 | |a MITOGEN ACTIVATED PROTEIN KINASE |
| 690 | 1 | 0 | |a MITOGEN ACTIVATED PROTEIN KINASE 1 |
| 690 | 1 | 0 | |a MITOGEN ACTIVATED PROTEIN KINASE 3 |
| 690 | 1 | 0 | |a ORTHOVANADIC ACID |
| 690 | 1 | 0 | |a PEPTIDE HORMONE |
| 690 | 1 | 0 | |a PROTEIN TYROSINE KINASE |
| 690 | 1 | 0 | |a VITAMIN D RECEPTOR |
| 690 | 1 | 0 | |a 4 AMINO 5 (4 METHYLPHENYL) 7 (TERT BUTYL)PYRAZOLO(3,4 D)PYRIMIDINE |
| 690 | 1 | 0 | |a 4-AMINO-5-(4-METHYLPHENYL)-7-(TERT-BUTYL)PYRAZOLO(3,4-D)PYRIMIDINE |
| 690 | 1 | 0 | |a CALCITRIOL RECEPTOR |
| 690 | 1 | 0 | |a ENZYME INHIBITOR |
| 690 | 1 | 0 | |a MITOGEN ACTIVATED PROTEIN KINASE |
| 690 | 1 | 0 | |a PHOSPHOTYROSINE |
| 690 | 1 | 0 | |a PROTEIN KINASE P60 |
| 690 | 1 | 0 | |a PROTEIN TYROSINE PHOSPHATASE |
| 690 | 1 | 0 | |a PYRAZOLE DERIVATIVE |
| 690 | 1 | 0 | |a PYRIMIDINE DERIVATIVE |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CELL MEMBRANE |
| 690 | 1 | 0 | |a CELL STRAIN MCF 7 |
| 690 | 1 | 0 | |a DRUG INHIBITION |
| 690 | 1 | 0 | |a ENZYME ACTIVITY |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a SIGNAL TRANSDUCTION |
| 690 | 1 | 0 | |a TRANSCRIPTION REGULATION |
| 690 | 1 | 0 | |a BREAST TUMOR |
| 690 | 1 | 0 | |a CELL NUCLEUS |
| 690 | 1 | 0 | |a CELL PROLIFERATION |
| 690 | 1 | 0 | |a DRUG ANTAGONISM |
| 690 | 1 | 0 | |a DRUG EFFECT |
| 690 | 1 | 0 | |a ENZYME ACTIVATION |
| 690 | 1 | 0 | |a ENZYMOLOGY |
| 690 | 1 | 0 | |a METABOLISM |
| 690 | 1 | 0 | |a PHOSPHORYLATION |
| 690 | 1 | 0 | |a PROTEIN BINDING |
| 690 | 1 | 0 | |a PROTEIN TRANSPORT |
| 690 | 1 | 0 | |a SERUM |
| 690 | 1 | 0 | |a TUMOR CELL LINE |
| 690 | 1 | 0 | |a BREAST NEOPLASMS |
| 690 | 1 | 0 | |a CALCITRIOL |
| 690 | 1 | 0 | |a CELL LINE, TUMOR |
| 690 | 1 | 0 | |a CELL MEMBRANE |
| 690 | 1 | 0 | |a CELL NUCLEUS |
| 690 | 1 | 0 | |a CELL PROLIFERATION |
| 690 | 1 | 0 | |a ENZYME ACTIVATION |
| 690 | 1 | 0 | |a ENZYME INHIBITORS |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a MITOGEN-ACTIVATED PROTEIN KINASES |
| 690 | 1 | 0 | |a PHOSPHORYLATION |
| 690 | 1 | 0 | |a PHOSPHOTYROSINE |
| 690 | 1 | 0 | |a PROTEIN BINDING |
| 690 | 1 | 0 | |a PROTEIN TRANSPORT |
| 690 | 1 | 0 | |a PROTEIN-TYROSINE-PHOSPHATASE |
| 690 | 1 | 0 | |a PROTO-ONCOGENE PROTEINS PP60(C-SRC) |
| 690 | 1 | 0 | |a PYRAZOLES |
| 690 | 1 | 0 | |a PYRIMIDINES |
| 690 | 1 | 0 | |a RECEPTORS, CALCITRIOL |
| 690 | 1 | 0 | |a SERUM |
| 690 | 1 | 0 | |a SIGNAL TRANSDUCTION |
| 700 | 1 | |a Rossi, A.M. | |
| 700 | 1 | |a Picotto, G. | |
| 700 | 1 | |a Benassati, S. | |
| 700 | 1 | |a Boland, R.L. | |
| 773 | 0 | |d 2004 |g v. 93 |h pp. 384-397 |k n. 2 |p J. Cell. Biochem. |x 07302312 |t Journal of Cellular Biochemistry | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-16544373001&doi=10.1002%2fjcb.20165&partnerID=40&md5=2de216329dd56c174d80a4356148d2f9 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1002/jcb.20165 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_07302312_v93_n2_p384_Capiati |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07302312_v93_n2_p384_Capiati |y Registro en la Biblioteca Digital |
| 961 | |a paper_07302312_v93_n2_p384_Capiati |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 82083 | ||